Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Autor: Guo-Qing Tang, Yalan Tang, Dhamnaskar, Ketki, Hoarty, Michelle D., Vyasamneni, Rohit, Vadysirisack, Douangsone D., Zhong Ma, Nanqun Zhu, Jian-Guo Wang, Bu, Charlie, Cong, Bestine, Palmer, Elizabeth, Duda, Petra W., Sayegh, Camil, Ricardo, Alonso

Publikováno v: Frontiers in Immunology; 2023, p1-11, 11p

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Autor: Douglas A. Treco, Dhamnaskar Ketki Ashok, Kathleen Seyb, Demarco Steven James, Vaishnavi Rajagopal, Michelle Denise Arata, Masha Fridkis-Hareli, Guo-Qing Tang, Hammer Robert Paul, Alonso Ricardo, Sylvia Tobe

Publikováno v: Blood. 126:939-939

Regulation of the terminal phase of the complement component pathway is a clinically validated approach for the therapeutic treatment of complement disorders. Inhibition of complement activation at the C5 level with the monoclonal antibody eculizumab

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b1a6558f3c22d74c96a694c42bad48f0
https://doi.org/10.1182/blood.v126.23.939.939

Preclinical Evaluation of RA101495, a Potent Cyclic Peptide Inhibitor of C5 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria

Autor: Ricardo, Alonso ^*, Arata, Michelle ^*, DeMarco, Steven ^*, Dhamnaskar, Ketki ^*, Hammer, Robert ^*, Fridkis-Hareli, Masha ^*, Rajagopal, Vaishnavi ^*, Seyb, Kathleen ^*, Tang, Guo-Qing ^*, Tobe, Sylvia ^*, Treco, Douglas ^*

Publikováno v: In Blood 3 December 2015 126(23):939-939

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Corrigendum: Zilucoplan, a macrocyclic peptide inhibitor of human complement component 5, uses a dual mode of action to prevent terminal complement pathway activation.

Autor: Tang GQ; UCB Pharma, Cambridge, MA, United States., Tang Y; UCB Pharma, Cambridge, MA, United States., Dhamnaskar K; Ra Pharmaceuticals, Cambridge, MA, United States., Hoarty MD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Vyasamneni R; Ra Pharmaceuticals, Cambridge, MA, United States., Vadysirisack DD; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ma Z; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Zhu N; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Wang JG; UCB Pharma, Cambridge, MA, United States., Bu C; UCB Pharma, Cambridge, MA, United States., Cong B; UCB Pharma, Cambridge, MA, United States., Palmer E; UCB Pharma, Cambridge, MA, United States., Duda PW; UCB Pharma, Cambridge, MA, United States., Sayegh C; UCB Pharma/Ra Pharmaceuticals, Cambridge, MA, United States., Ricardo A; Ra Pharmaceuticals, Cambridge, MA, United States.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Sep 25; Vol. 14, pp. 1282155. Date of Electronic Publication: 2023 Sep 25 (Print Publication: 2023).